Receptors, Vasoactive Intestinal Polypeptide, Type I
"Receptors, Vasoactive Intestinal Polypeptide, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pituitary adenylate cyclase-activating polypeptide receptor subtype that binds both PACAP and VASOACTIVE INTESTINAL PEPTIDE. It is found predominately in the BRAIN.
MeSH Number(s)
D12.776.543.750.100.665.760
D12.776.543.750.100.900.520
Concept/Terms
Receptors, Vasoactive Intestinal Polypeptide, Type I- Receptors, Vasoactive Intestinal Polypeptide, Type I
- VIP 1 Receptor
- Receptor, VIP 1
- VIP1 Receptor
- VIP1 Receptors
- Receptors, VIP1
- VIPR1 Protein
- VPAC1 Receptor
- Receptor, VPAC1
- PACAP Receptors, Type II
- PACAP Type II Receptor
- PACAPR-2 Protein
- PACAPR 2 Protein
- Pituitary Adenylate Cyclase-Activating Peptide Receptor Type II
- Pituitary Adenylate Cyclase Activating Peptide Receptor Type II
- Receptor, VIP1
- Receptors, Pituitary Adenylate Cyclase-Activating Peptide, Type II
- Vasoactive Intestinal Peptide 1 Receptor
- Vasoactive Intestinal Peptide Receptor 1
- Vasoactive Intestinal Peptide Receptors, Type I
- VIP Receptors, Type I
- VIP-1 Receptor
- Receptor, VIP-1
Below are MeSH descriptors whose meaning is more general than "Receptors, Vasoactive Intestinal Polypeptide, Type I".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.100]
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide [D12.776.543.750.100.665]
- Receptors, Vasoactive Intestinal Polypeptide, Type I [D12.776.543.750.100.665.760]
- Receptors, Vasoactive Intestinal Peptide [D12.776.543.750.100.900]
- Receptors, Vasoactive Intestinal Polypeptide, Type I [D12.776.543.750.100.900.520]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vasoactive Intestinal Polypeptide, Type I".
This graph shows the total number of publications written about "Receptors, Vasoactive Intestinal Polypeptide, Type I" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Vasoactive Intestinal Polypeptide, Type I" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
Below are the most recent publications written about "Receptors, Vasoactive Intestinal Polypeptide, Type I" by people in Profiles.
-
Low levels of vasoactive intestinal peptide are associated with Chagas disease cardiomyopathy. Hum Immunol. 2013 Oct; 74(10):1375-81.
-
Effect of VIP on intracellular [Ca2+], extracellular regulated kinase 1/2, and secretion in cultured rat conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2013 Apr 23; 54(4):2872-84.
-
Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance. Histol Histopathol. 2012 08; 27(8):1093-101.
-
Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochim Biophys Acta. 2012 Oct; 1823(10):1676-85.
-
RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol. 2012 Jan 02; 348(1):241-6.
-
Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer Lett. 2010 Dec 18; 299(1):11-21.
-
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides. 2010 Nov; 31(11):2035-45.
-
Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol. 2005 Jun; 26(6):1629-35.
-
Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. Gynecol Endocrinol. 2005 Jun; 20(6):327-33.
-
Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept. 2004 Jun 15; 119(1-2):69-75.